This article was originally published in The Gray Sheet
Executive SummaryPlans to use part of an anticipated $6.7 mil. in net proceeds from offering of 3 mil. units to support "ongoing and planned clinical trials" of Argidene Gel, a treatment for diabetic foot ulcers (previously called Telio-Derm), and TP-9201, which is being developed to treat conditions associated with platelet aggregation, the San Diego-based company says in a prospectus for the offering. Telios submitted a premarket approval application for Argidene Gel in March 1993 ("The Gray Sheet" April 5, 1993, In Brief) and has filed an investigational new drug application for TP-9201. The proceeds also will be used for scheduled repayments of obligations under equipment leases and notes payable. Each unit in the offering consists of one share of convertible preferred stock and one warrant to purchase a share of common stock. The placement agent for the offering is Hambrecht & Quist
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.